PHARMACEUTICAL COMPOSITION FOR TREATING RETINAL DYSTROPHIES, COMPRISING NKX3.2 AND FRAGMENT THEREOF AS ACTIVE INGREDIENTS
A pharmaceutical composition contains Nkx3.2 and a fragment thereof as an active ingredient. The Nkx3.2 and/or the fragment thereof inhibit(s) retinal degeneration caused by oxidative stress and preserve(s) visual function. In addition, the Nkx3.2 and/or the fragment thereof inhibit(s) cell death due to the oxidative stress of retinal pigment epithelial cells and inhibit(s) choroidal neovascularization and retinal edema. Therefore, a composition containing the Nkx3.2 and/or the fragment thereof as active ingredient(s) can be effectively used for preventing or treating retinal dystrophies or macular degeneration..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Europäisches Patentamt - (2021) vom: 24. Juni Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
KIM DAE-WON [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Sonstige Themen: |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-06-24, Last update posted on www.tib.eu: 2023-06-22, Last updated: 2023-06-30 |
---|
Patentnummer: |
US2021187065 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA01185989X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA01185989X | ||
003 | DE-627 | ||
005 | 20230630124316.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210729s2021 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA01185989X | ||
035 | |a (EPA)US2021187065 | ||
035 | |a (EPA)70282952 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a KIM DAE-WON |e verfasserin |4 aut | |
245 | 1 | 0 | |a PHARMACEUTICAL COMPOSITION FOR TREATING RETINAL DYSTROPHIES, COMPRISING NKX3.2 AND FRAGMENT THEREOF AS ACTIVE INGREDIENTS |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2021-06-24, Last update posted on www.tib.eu: 2023-06-22, Last updated: 2023-06-30 | ||
520 | |a A pharmaceutical composition contains Nkx3.2 and a fragment thereof as an active ingredient. The Nkx3.2 and/or the fragment thereof inhibit(s) retinal degeneration caused by oxidative stress and preserve(s) visual function. In addition, the Nkx3.2 and/or the fragment thereof inhibit(s) cell death due to the oxidative stress of retinal pigment epithelial cells and inhibit(s) choroidal neovascularization and retinal edema. Therefore, a composition containing the Nkx3.2 and/or the fragment thereof as active ingredient(s) can be effectively used for preventing or treating retinal dystrophies or macular degeneration. | ||
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a che | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a 615 | |
700 | 0 | |a YUM YOUNG-NA |4 aut | |
700 | 0 | |a RYU HEUI-YOUNG |4 aut | |
700 | 0 | |a JEONG DA-UN |4 aut | |
700 | 0 | |a CHOI SEUNG-WON |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 24. Juni |
773 | 1 | 8 | |g year:2021 |g day:24 |g month:06 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/70282952/publication/US2021187065A1?q=US2021187065 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
936 | u | w | |j 2021 |b 24 |c 06 |
951 | |a AR | ||
952 | |j 2021 |b 24 |c 06 |